Ariel B Neikrug1, Lianqi Liu2, Julie A Avanzino2, Jeanne E Maglione2, Loki Natarajan3, Lenette Bradley2, Alex Maugeri2, Jody Corey-Bloom4, Barton W Palmer5, Jose S Loredo6, Sonia Ancoli-Israel7. 1. San Diego State University and University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA. 2. Department of Psychiatry, University of California San Diego, San Diego, CA. 3. Department of Family and Preventive Medicine, University of California San Diego, San Diego, CA. 4. Department of Neurosciences, University of California San Diego, San Diego, CA. 5. San Diego State University and University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA ; Department of Psychiatry, University of California San Diego, San Diego, CA ; Veterans Medical Research Foundation, San Diego, CA. 6. Department of Medicine, University of California San Diego, San Diego, CA. 7. San Diego State University and University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA ; Department of Psychiatry, University of California San Diego, San Diego, CA ; Department of Medicine, University of California San Diego, San Diego, CA ; Veterans Affairs Center of Excellence for Stress and Mental Health, San Diego, CA.
Abstract
STUDY OBJECTIVES:Obstructive sleep apnea (OSA), common in Parkinson disease (PD), contributes to sleep disturbances and daytime sleepiness. We assessed the effect of continuous positive airway pressure (CPAP) on OSA, sleep, and daytime sleepiness in patients with PD. DESIGN: This was a randomized placebo-controlled, crossover design. Patients with PD and OSA were randomized into 6 w of therapeutic treatment or 3 w of placebo followed by 3 w of therapeutic treatment. Patients were evaluated by polysomnography (PSG) and multiple sleep latency test (MSLT) pretreatment (baseline), after 3 w, and after 6 w of CPAP treatment. Analyses included mixed models, paired analysis, and within-group analyses comparing 3 w to 6 w of treatment. SETTING: Sleep laboratory. PARTICIPANTS: Thirty-eight patients with PD (mean age = 67.2 ± 9.2 y; 12 females). INTERVENTION: Continuous positive airway pressure. MEASUREMENTS: PSG OUTCOME MEASURES: sleep efficiency, %sleep stages (N1, N2, N3, R), arousal index, apnea-hypopnea index (AHI), and % time oxygen saturation < 90% (%time SaO2 < 90%). MSLT outcome measures: mean sleep-onset latency (MSL). RESULTS: There were significant group-by-time interactions for AHI (P < 0.001), % time SaO2 < 90% (P = 0.02), %N2 (P = 0.015) and %N3 (P = 0.014). Subjects receiving therapeutic CPAP showed significant decrease in AHI, %time SaO2 < 90%, %N2, and significant increase in %N3 indicating effectiveness of CPAP in the treatment of OSA, improvement in nighttime oxygenation, and in deepening sleep. The paired sample analyses revealed that 3 w of therapeutic treatment resulted in significant decreases in arousal index (t = 3.4, P = 0.002). All improvements after 3 w were maintained at 6 w. Finally, 3 w of therapeutic CPAP also resulted in overall decreases in daytime sleepiness (P = 0.011). CONCLUSIONS:Therapeutic continuous positive airway pressure versus placebo was effective in reducing apnea events, improving oxygen saturation, and deepening sleep in patients with Parkinson disease and obstructive sleep apnea. Additionally, arousal index was reduced and effects were maintained at 6 weeks. Finally, 3 weeks of continuous positive airway pressure treatment resulted in reduced daytime sleepiness measured by multiple sleep latency test. These results emphasize the importance of identifying and treating obstructive sleep apnea in patients with Parkinson disease.
RCT Entities:
STUDY OBJECTIVES:Obstructive sleep apnea (OSA), common in Parkinson disease (PD), contributes to sleep disturbances and daytime sleepiness. We assessed the effect of continuous positive airway pressure (CPAP) on OSA, sleep, and daytime sleepiness in patients with PD. DESIGN: This was a randomized placebo-controlled, crossover design. Patients with PD and OSA were randomized into 6 w of therapeutic treatment or 3 w of placebo followed by 3 w of therapeutic treatment. Patients were evaluated by polysomnography (PSG) and multiple sleep latency test (MSLT) pretreatment (baseline), after 3 w, and after 6 w of CPAP treatment. Analyses included mixed models, paired analysis, and within-group analyses comparing 3 w to 6 w of treatment. SETTING: Sleep laboratory. PARTICIPANTS: Thirty-eight patients with PD (mean age = 67.2 ± 9.2 y; 12 females). INTERVENTION: Continuous positive airway pressure. MEASUREMENTS: PSG OUTCOME MEASURES: sleep efficiency, %sleep stages (N1, N2, N3, R), arousal index, apnea-hypopnea index (AHI), and % time oxygen saturation < 90% (%time SaO2 < 90%). MSLT outcome measures: mean sleep-onset latency (MSL). RESULTS: There were significant group-by-time interactions for AHI (P < 0.001), % time SaO2 < 90% (P = 0.02), %N2 (P = 0.015) and %N3 (P = 0.014). Subjects receiving therapeutic CPAP showed significant decrease in AHI, %time SaO2 < 90%, %N2, and significant increase in %N3 indicating effectiveness of CPAP in the treatment of OSA, improvement in nighttime oxygenation, and in deepening sleep. The paired sample analyses revealed that 3 w of therapeutic treatment resulted in significant decreases in arousal index (t = 3.4, P = 0.002). All improvements after 3 w were maintained at 6 w. Finally, 3 w of therapeutic CPAP also resulted in overall decreases in daytime sleepiness (P = 0.011). CONCLUSIONS: Therapeutic continuous positive airway pressure versus placebo was effective in reducing apnea events, improving oxygen saturation, and deepening sleep in patients with Parkinson disease and obstructive sleep apnea. Additionally, arousal index was reduced and effects were maintained at 6 weeks. Finally, 3 weeks of continuous positive airway pressure treatment resulted in reduced daytime sleepiness measured by multiple sleep latency test. These results emphasize the importance of identifying and treating obstructive sleep apnea in patients with Parkinson disease.
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: Ysbrand D Van Der Werf; Ellemarije Altena; Menno M Schoonheim; Ernesto J Sanz-Arigita; José C Vis; Wim De Rijke; Eus J W Van Someren Journal: Nat Neurosci Date: 2009-01-18 Impact factor: 24.884
Authors: Jana R Cooke; Sonia Ancoli-Israel; Lianqi Liu; Jose S Loredo; Loki Natarajan; Barton S Palmer; Feng He; Jody Corey-Bloom Journal: Sleep Med Date: 2009-08-20 Impact factor: 3.492
Authors: Marta Kaminska; Victoria P Mery; Anne-Louise Lafontaine; Ann Robinson; Andrea Benedetti; Priti Gros; R John Kimoff Journal: J Clin Sleep Med Date: 2018-05-15 Impact factor: 4.062
Authors: Nadia Gosselin; Andrée-Ann Baril; Ricardo S Osorio; Marta Kaminska; Julie Carrier Journal: Am J Respir Crit Care Med Date: 2019-01-15 Impact factor: 21.405
Authors: Priti Gros; Victoria P Mery; Anne-Louise Lafontaine; Ann Robinson; Andrea Benedetti; R John Kimoff; Marta Kaminska Journal: Sleep Breath Date: 2015-06-13 Impact factor: 2.816
Authors: Alexandrea L Harmell; Ariel B Neikrug; Barton W Palmer; Julie A Avanzino; Lianqi Liu; Jeanne E Maglione; Loki Natarajan; Jody Corey-Bloom; Jose S Loredo; Sonia Ancoli-Israel Journal: Sleep Med Date: 2016-02-10 Impact factor: 3.492
Authors: Ariel B Neikrug; Jeanne E Maglione; Lianqi Liu; Loki Natarajan; Julie A Avanzino; Jody Corey-Bloom; Barton W Palmer; Jose S Loredo; Sonia Ancoli-Israel Journal: J Clin Sleep Med Date: 2013-11-15 Impact factor: 4.062